There are about 20,000 genes in the human genome that can transcribe and translate up to 1000,000,<> or more proteins. This is partly due to the fact that individual genes produce different ribonucleic acid (RNA) isoforms during transcription and countless proteins with different structures during translation. From amino acid sequence and structural changes, to post-translational modifications (PTMs), to functional changes resulting from interactions between proteins. All of these protein forms will also vary in different states of health and disease. As the basic research of bioomics, proteomics plays an important role in the study of finding biomarkers and innovative drug target information, biometabolic transformation and drug toxicity and side effects.

As a cutting-edge comprehensive research discipline, proteomics experiments require special attention to every operational detail, from sample preparation to mass spectrometry on-machine detection and a large number of post-experimental data analysis. Scientific research teams often need the help of professional third-party scientific research technology service providers because they do not have soft and hard conditions, so a number of proteomics scientific research service types of companies have been born.

According to SVB Leerink research, the potential market size of proteomics can be analyzed with reference to the current industrial scale of genomics, which is currently represented by next-generation sequencing technology as high as $910 billion, compared with the potential market size of proteomics in life science tools and diagnostics is expected to reach $750 billion in the future.

The boom in the genomics industry occurred within 2003 years of the completion of the Human Genome Project (HGP) sequencing (20). Scientific breakthroughs represented by human gene sequencing, breakthroughs in the advent of second-generation sequencers represented by Illumina, and the continuous improvement of the efficiency of gene sequencing, have reduced the cost of whole genome sequencing from $300 million to $500, making the application field of genomics no longer limited to the field of scientific research, and the popularization and application of genomics technology in medical testing and clinical treatment has been realized. Represented by BGI and Novo Zhiyuan, it takes advantage of China's engineer dividends to provide scientific research and technical services as its early business model, taking root in the Chinese market and growing. By continuously expanding the application field of genomics, BGI has been able to develop prenatal examination services, basic research and clinical application services for infection prevention and control, and tumor prevention and control and translational medicine services in the field of biological health.

The growth of current research activities in proteomics is similar to the trajectory of early genomics. The International Human Proteome Project (HPP) was launched in 2010 and the first sequence sketch of human proteomics was published in 2020. Although advances in mass spectrometry such as the Thermo Scientific Orbitrap mass spectrometer and the Bruker 10D mass spectrometer have greatly advanced the proteomics industry over the past 4 years, the cost of proteomic analysis remains high due to the complexity of proteomics. In addition, the popularization of new technologies has also limited the expansion of proteomics in more applications such as clinical medical diagnosis and precision medicine. With the application of artificial intelligence technology, the improvement of automatic standardization of sample preparation and mass spectrometry analysis, and the continuous improvement of mass spectrometry analysis performance, it is expected to further improve the efficiency and reduce the cost of proteomic analysis, thereby clearing the obstacles for proteomics in applications other than scientific research.

Bruker mass spectrometry (timsTOF pro)

Thermo Fisher Scientific mass spectrometry (Orbitrap Exploris™ 480 MS)